ArticleCancer immunology, immunotherapy : CII2008
Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- The information overload, immunology and their relationship to world health.Open biology · 2025Review
- Characterization of mitochondrial metabolism related molecular subtypes and immune infiltration in colorectal adenocarcinoma.Scientific reports · 2024Article
- Article
- Review
- Neutrophil in the suppressed immune microenvironment: Critical prognostic factor for lung adenocarcinoma patients with KEAP1 mutation.Frontiers in genetics · 2024Article
- Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer.Discover oncology · 2023Review
- Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.Cells · 2023Review
- Article
- The Problem of Host and Pathogen Genetic Variability for Developing Strategies of Universally Efficacious Vaccination against and Personalised Immunotherapy of Tuberculosis: Potential Solutions?International journal of molecular sciences · 2023Article
- Identification of the mitophagy-related diagnostic biomarkers in hepatocellular carcinoma based on machine learning algorithm and construction of prognostic model.Frontiers in oncology · 2023Article
- Article
- Defending and integrating an organism by the immune system.Scandinavian journal of immunology · 2022Review
- Facing the Increased Prevalence of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Analyzing some concepts of immune regulation of the last three decades: Fostering greater research resilience despite the information overload. A personal view.Frontiers in immunology · 2022Article
- Next frontier in tumor immunotherapy: macrophage-mediated immune evasion.Biomarker research · 2021Review
- The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed.Frontiers in immunology · 2021Article
- Molecular model linking Th2 polarized M2 tumour-associated macrophages with deaminase-mediated cancer progression mutation signatures.Scandinavian journal of immunology · 2019Article
- On Analyzing How the Th1/Th2 Phenotype of an Immune Response Is Determined: Classical Observations Must Not Be Ignored.Frontiers in immunology · 2019Review
- Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.Frontiers in immunology · 2018Article
- Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.Cancer science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Observations show that humans and animals respond immunologically to most cancers. Why does the immune system then fail to control cancer? We argue from the literature that there is a commonality in the regulation of responses against most murine tumors, and that a major mechanism of escape may be deviation of an effective Th1, cytotoxic T lymphocyte response to a less effective response with a Th2 component. We examined this hypothesis with two well-studied murine tumors. We found, following primary tumor implantation, that resistance correlates with Th1 responses and IgG2a antibody production and progression with mixed Th1/Th2 responses and production of IgG1 and IgG2a antibodies. Resistance is associated with a modulation of the anti-tumor response towards the Th1 pole in both systems. We conclude that the immune responses against these two tumors are in accord with our hypothesis, and argue that this is likely to be true of many human and murine tumors. The correlation of IgG isotype of anti-tumor antibody with the Th1/Th2 nature of the anti-tumor response readily allows one to longitudinally monitor the changing nature of the anti-tumor response. We suggest that such monitoring can guide immunotherapy to maximize the effectiveness of the host's immune response against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.